Drug Profile
Paclitaxel plus ritonavir - Modra Pharmaceuticals
Alternative Names: ModraPac 005; ModraPac 005/rLatest Information Update: 11 Jul 2022
Price :
$50
*
At a glance
- Originator Modra Pharmaceuticals
- Class Amides; Antineoplastics; Carbamates; Diterpenes; Paclitaxels; Small molecules; Taxanes; Thiazoles
- Mechanism of Action Angiogenesis inhibitors; Cytochrome P 450 enzyme system inhibitors; P-glycoprotein inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 11 Jul 2022 Paclitaxel plus ritonavir is still in phase I trials for Solid tumours in Netherlands (PO) (Modra Pharmaceuticals pipeline, July 2022)
- 27 Jan 2022 Paclitaxel plus ritonavir is still in phase I trials for Solid tumours (Modra Pharmaceuticals pipeline, January 2022)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Solid tumours (Combination therapy) in Netherlands (PO, Tablet)